Welcome to our dedicated page for Arrowhead Pharma SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents give detailed insight into Arrowhead’s RNA interference (RNAi) pipeline, capital structure, collaborations, and material events affecting ARWR stock.
Arrowhead’s filings include Form 8-K current reports describing key developments such as approvals for REDEMPLO (plozasiran) in familial chylomicronemia syndrome, Breakthrough Therapy designation for investigational plozasiran in severe hypertriglyceridemia, interim clinical data for obesity candidates ARO-INHBE and ARO-ALK7, and the initiation of a Phase 1/2a study of ARO-MAPT for tauopathies including Alzheimer’s disease. Other 8-Ks outline collaboration agreements, such as the exclusive license with Novartis for ARO-SNCA, and agreements involving Visirna Therapeutics and Sanofi in Greater China.
Filings also cover Arrowhead’s capital markets transactions, including underwriting agreements for public offerings of common stock, pre-funded warrants, and 0.00% convertible senior notes due 2032. These documents describe offering terms, use of proceeds for research and development, clinical trials, commercialization activities, and related capped call transactions intended to manage potential dilution upon note conversion.
On Stock Titan, Arrowhead’s SEC filings are updated in near real time from EDGAR. Users can review annual and quarterly reports when available, as well as current reports and exhibits that detail licensing deals, clinical milestones, and regulatory actions. AI-powered summaries help explain complex sections of 10-Ks, 10-Qs, and 8-Ks in plain language, and specialized views make it easier to track insider-related disclosures and other material information relevant to ARWR investors.
Arrowhead Pharmaceuticals’ Chief Executive Officer and director Christopher Anzalone reported preset stock sales in December 2025. On December 19, 2025, he sold several blocks of Arrowhead common stock, including 3,979 shares at a weighted average price of $66.67, 8,147 shares at $68.01, and 1,319 shares at $68.48. On December 22, 2025, he sold additional blocks of 10,012 shares at a weighted average price of $68.33 and 2,574 shares at $68.85.
The filing states that all of these transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted by the reporting person. After these sales, Anzalone beneficially owns 3,805,926 shares of Arrowhead common stock directly, which includes shares underlying previously reported restricted stock units that continue to be subject to vesting conditions.
Arrowhead Pharmaceuticals director reports planned stock sales under a Rule 10b5-1 trading plan. On 12/19/2025, the reporting person sold three blocks of Arrowhead common stock: 3,090 shares at a weighted average price of $66.7, 6,083 shares at a weighted average price of $68.04, and 827 shares at a weighted average price of $68.48.
The filing states these sales were made under a pre‑established 10b5-1 trading plan adopted in accordance with securities regulations. After these transactions, the reporting person beneficially owns 33,600 shares of Arrowhead common stock, which includes shares underlying restricted stock units that remain subject to vesting conditions.
Arrowhead Pharmaceuticals reported an insider equity award for one of its directors. On 12/16/2025, the director received 7,819 shares of common stock through restricted stock units at a price of $0. These shares will vest in a single installment on the first anniversary of the grant date, conditioned on the director’s continued service with the company. Following this grant, the director beneficially owns 46,215 shares of Arrowhead Pharmaceuticals common stock in direct ownership.
Arrowhead Pharmaceuticals director reports new stock award. A board member of Arrowhead Pharmaceuticals received 7,819 shares of common stock on 12/16/2025 through restricted stock units. These shares were acquired at a stated price of $0, reflecting an equity grant rather than an open-market purchase. After this award, the director beneficially owns 43,600 shares of Arrowhead common stock directly.
The 7,819 shares represent underlying restricted stock units that will vest in a single installment on the first anniversary of the grant date, as long as the director continues to serve the company through that date. This filing documents the equity-based compensation granted to the director and updates the total number of shares reported as beneficially owned.
Arrowhead Pharmaceuticals director reports stock grant. A director of Arrowhead Pharmaceuticals, Inc. reported receiving 7,819 shares of common stock on 12/16/2025 at a price of $0. These shares represent restricted stock units that will vest in a single installment on the first anniversary of the grant date, as long as the director continues to serve the company through that date.
After this grant, the director beneficially owns 64,930 shares of Arrowhead common stock in direct ownership. The filing indicates it was made by a single reporting person serving as a director of the company.
Arrowhead Pharmaceuticals reported insider equity activity by its chief executive officer and director in December 2025. On December 12, 2025, he received 180,000 shares underlying restricted stock units, which will vest in four equal annual installments.
On December 15 and 16, 2025, he sold multiple blocks of common stock, including 100,532 shares at a weighted average price of $68.67 and 21,321 shares at $69.28, exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. After these transactions, he beneficially owned 3,916,957 Arrowhead common shares, which include previously reported shares underlying restricted stock units that remain subject to vesting conditions.
Arrowhead Pharmaceuticals (ARWR) files its annual report describing a transition from a pure R&D biotech to a commercial-stage RNA interference company. The business centers on its proprietary TRiM platform, which uses targeted siRNA to silence disease-causing genes across multiple tissues.
A major milestone is the 2025 FDA approval and U.S. commercial launch of REDEMPLO (plozasiran) for adults with Familial Chylomicronemia Syndrome, the first and only FDA‑approved siRNA studied in both genetically confirmed and clinically diagnosed FCS patients. The company is running fully enrolled Phase 3 studies in severe hypertriglyceridemia and plans a supplemental NDA in 2026.
Arrowhead reports 18 company-discovered drug candidates in clinical trials, spanning cardiovascular, liver, obesity, renal, pulmonary, CNS and rare neuromuscular diseases, plus a discovery pipeline. It highlights extensive collaborations with GSK, Takeda, Amgen, Sarepta and Novartis that can generate milestones and royalties, and an IP estate of about 643 issued patents and roughly 833 pending applications worldwide.
Arrowhead Pharmaceuticals, Inc. reported that it has announced and commented on its fiscal 2025 financial results for the period ended September 30, 2025. The announcement was made on November 25, 2025.
The company provided these results in a press release that is included as Exhibit 99.1, with an additional Exhibit 104 covering the interactive data for the cover page. The report was signed on behalf of the company by Chief Financial Officer Daniel Apel.
Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare lipid disorder. This marks a significant regulatory milestone for the company, adding an FDA‑approved therapy to its portfolio. Arrowhead also held a conference call to discuss the approval and provided a detailed press release and slide presentation as exhibits to the report.
Arrowhead Pharmaceuticals amended its annual report to disclose a major collaboration with Sarepta Therapeutics and results for fiscal 2024. The company expects to receive $500.0M upfront in cash plus $325.0M as an equity investment and $250.0M in five annual installments, with an additional near-term $300.0M payment opportunity and up to $10.0B in future milestones and tiered royalties. Arrowhead sold 11,926,301 shares to Sarepta at $27.25 per share for approximately $325.0M.
Pipeline and platform highlights include advancement of multiple RNAi programs (ARO-INHBE, ARO-ALK7, ARO-DM1, ARO-C3, ARO-CFB, ARO-RAGE and others) with Phase 1/2a filings and Phase 2/3 results for cardiometabolic candidates. Financially, fiscal 2024 revenue was $3.6M, net loss was $599.5M (diluted loss per share ($5.00)), and cash and investments totaled $681.0M at September 30, 2024.